Share

    


In This Section

Home / Learn / Multiple Myeloma

Multiple Myeloma

Multiple myeloma, also known as myeloma, is the third most common hematologic cancer (cancer of the blood). However, compared to more frequently occurring cancers (e.g., breast, prostate, lung, and colorectal cancers), multiple myeloma is relative rare and accounts for only 1.6 percent of diagnoses each year. For 2018, the American Cancer Society estimates that 30,770 new cases of myeloma will be diagnosed in the U.S.1 Due to the less common occurrence of multiple myeloma, providers are less likely to diagnosis and treat these patients on a regular basis. 

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: Cancer J Clin. 2018;68:7-30.

Featured Programs

Multidisciplinary Multiple Myeloma Care

Guided by an expert Advisory Committee, this ACCC education project aims to support the multidisciplinary cancer care team in diagnosing, testing, and treating patients with multiple myeloma. This project seeks to:

  • raise awareness about provider education needs related to this patient population;
  • provide vetted, designated resources for unmet education needs; and
  • establish a network of multidisciplinary team members with interest and expertise in caring for patient with multiple myeloma.

Through this project, a new ACCC publication, Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery, provides a summary of recent updates in myeloma management, along with profiles that describe how three cancer programs—a community-based comprehensive program, an academic medical center, and an NCI-designated program—are delivering multidisciplinary care to this patient population.

Learn More

Transplant Treatment Path

The ACCC educational initiative, The Transplant Treatment Path: Optimizing Patient-Centered Care for ASCT in Multiple Myeloma aimed at improving provider communication to optimize the treatment of multiple myeloma patients in the community cancer center pre- and post-autologous stem cell transplant (ASCT)
Learn More

In the News